Sulfanilamide (When ATH J01EB06)

When ATH:
J01EB06

Characteristic.

It refers to a short-acting drug sulfanilamidnym. Sulfanilamide - a white crystalline powder;, slightly bitter taste with a sweet aftertaste. Easy soluble in boiling water (1:2), hard - ethanol (1:37), soluble in solutions of hydrochloric acid, caustic alkali, acetone (1:5), glycerin, propylene glycol; practically insoluble in ether, xloroforme, benzene, petroleum ether. Molecular weight - 172,21.

It is also used in the form of sodium metansulfata (Streptocide soluble) - A white crystalline powder; soluble in water, practically insoluble in organic solvents.

Pharmacological action.
Antimicrobial.

Application.

Locally: tonsillitis, purulent inflammation of the skin, infected wounds of various etiologies (incl. ulcers, cracks), furunkul, carbuncle, pyoderma, folliculitis, mug, acne vulgaris, impetigo, burns (I и II степени).

Contraindications.

Hypersensitivity (incl. to other sulfone- and sulfonamides), diseases of the hematopoietic system, anemia, renal / hepatic insufficiency, vrozhdennыy deficiency of glucose-6-fosfatdegidrogenazы, azotemia, porphyria.

Restrictions apply.

Pregnancy, lactation.

Pregnancy and breast-feeding.

When systemic absorption sulfanilamide can quickly pass through the placenta and is found in fetal blood (concentration in the blood of the fetus is 50-90% of that in maternal blood), and cause toxic effects. Safety of sulfanilamide in pregnancy has not been established. Unknown, whether sulfanilamide cause adverse fetal effects when taking pregnant women. In experimental studies in rats and mice, treated during pregnancy, some sulfonamides (including sulfanilamide) short, Medium and long-acting inwardly in high doses (in 7-25 times greater than the therapeutic dose for oral human), It shows a significant increase in the incidence of cleft palate and other malformations in the fetus bones.

Penetrates into breast milk, may cause kernicterus in newborns.

Side effects.

Allergic reactions; prolonged topical application in large quantities - systemic action: headache, dizziness, paraesthesia, tachycardia, nausea, vomiting, dyspepsia, leukopenia, agranulocytosis, kristallurija, cyanosis.

Cooperation.

Myelotoxicity drugs increase haematotoxicity.

Dosing and Administration.

Locally. When superficial infections of the skin and mucous membranes of the nose and ear, burns, ulcers, etc.. used in the form 10% ointment, 5% liniment or powder. Liniment or ointment applied directly to the skin surface or spread on gauze; dressings produced in 1-2 days. With deep wounds sulfanilamide introduced into the wound cavity in the form of finely ground powder sterilized (510-15 g), Once appointed, or other antibacterial sulfa drugs inside. Mixed with sulfathiazole, benzylpenicillin and ephedrine sometimes used topically (in acute rhinitis) powder (blowing or pulling it on the nose when inhaling).

Precautions.

With prolonged use is necessary to conduct the analysis of peripheral blood.